Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Top Page
Galera Therapeutics
(OTC:GRTX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.05
▲(135.00% Upside)
Action:ReiteratedDate:03/26/26
The score is held back primarily by weak financial performance (no revenue, ongoing operating losses, and limited evidence of sustainable cash generation), despite improved balance-sheet positioning in 2025. Technicals are relatively supportive with an uptrend and positive MACD, while valuation signals are unreliable due to likely non-operating earnings. The corporate event modestly helps by improving capital-structure flexibility but carries dilution risk.
Positive Factors
Deleveraging / Balance-sheet repair
Elimination of debt and a shift to modest positive equity in 2025 materially reduces near-term solvency risk. This repair provides a firmer capital cushion and more strategic optionality for hiring, trial funding, or partnering over the next several quarters, improving survivability.
Negative Factors
No revenue / pre-revenue status
A multi-year absence of revenue leaves the company dependent on external capital rather than operating cash flows. Without validated commercial products or recurring sales, funding needs remain structural and raise long-term dilution and sustainability concerns for development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging / Balance-sheet repair
Elimination of debt and a shift to modest positive equity in 2025 materially reduces near-term solvency risk. This repair provides a firmer capital cushion and more strategic optionality for hiring, trial funding, or partnering over the next several quarters, improving survivability.
Read all positive factors
Galera Therapeutics (GRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.11M
Dividend YieldN/A
Average Volume (3M)63.57K
Price to Earnings (P/E)<0.1
Beta (1Y)0.69
Revenue GrowthN/A
EPS Growth63.89%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,462,390
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap-1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Galera Therapeutics Business Overview & Revenue Model
Company Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese ...
How the Company Makes Money
null...
Galera Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -3.84M | -259.00K | -114.00K | -778.00K |
| EBITDA | -6.04M | -20.16M | -70.24M | -50.61M | -72.56M |
| Net Income | 149.05M | -18.96M | -59.08M | -62.22M | -80.53M |
Balance Sheet | |||||
| Total Assets | 7.20M | 10.10M | 26.14M | 44.04M | 83.31M |
| Cash, Cash Equivalents and Short-Term Investments | 6.38M | 8.29M | 18.26M | 31.60M | 71.22M |
| Total Debt | 0.00 | 151.05M | 1.25M | 44.00K | 302.00K |
| Total Liabilities | 645.00K | 153.77M | 157.33M | 153.22M | 141.31M |
| Stockholders Equity | 6.55M | -143.67M | -131.19M | -109.18M | -58.00M |
Cash Flow | |||||
| Free Cash Flow | -6.05M | -12.14M | -44.91M | -43.45M | -68.24M |
| Operating Cash Flow | -6.05M | -12.14M | -44.85M | -43.43M | -67.96M |
| Investing Cash Flow | 3.50M | -46.00K | 27.29M | 23.99M | 5.24M |
| Financing Cash Flow | 635.00K | 2.22M | 31.50M | 3.89M | 66.71M |
Galera Therapeutics Technical Analysis
Positive
0.02
Price Trends
0.03
Positive
0.03
Positive
0.02
Positive
Market Momentum
<0.01
Positive
50.19
Neutral
-11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of -11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRTX.
Galera Therapeutics Risk Analysis
Galera Therapeutics disclosed 47 risk factors in its most recent earnings report. Galera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $34.28M | -3.95 | -61.62% | ― | 4455.07% | 77.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.11M | <0.01 | 13.71% | ― | ― | 63.89% | |
44 Neutral | $2.05M | ― | ― | ― | 178.82% | -4121.10% | |
| ― | $874.56K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
GRTX
Galera Therapeutics
0.04
0.02
64.00%
QCLS
Q/C Technologies
3.57
-22.18
-86.14%
SCNI
Scinai Immunotherapeutics
0.59
-1.61
-73.18%
EVAX
Evaxion Biotech
4.11
2.76
204.44%
ONCO
Onconetix
1.22
-23.43
-95.05%
Galera Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Galera Therapeutics Updates Preferred Stock Conversion Provisions
Positive
Feb 18, 2026
On February 12, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment with the Delaware Secretary of State to modify the terms of its Series B Non-Voting Convertible Preferred Stock. The amendment permits the company’s board of di...
Business Operations and StrategyExecutive/Board Changes
Galera Therapeutics Grants Retention Bonus to Key Officer
Neutral
Feb 12, 2026
On February 6, 2026, Galera Therapeutics, Inc. entered into a letter agreement with Chief Accounting Officer, Treasurer, and Secretary Joel Sussman that provides retention-based cash bonus payments tied to the timely completion and filing of certa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.